Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSS59
- Development stage
- Phase 1
- Lead developer
- 3SBio
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SSS59 is a trispecific T-cell engager (TriTE) designed for the treatment of advanced cancers, particularly solid tumors. Its mechanism of action involves simultaneously targeting **CD28**, **CD3**, and **MUC17**. The drug acts as a CD28 inhibitor, CD3 stimulant, and MUC17 inhibitor, thereby modulating T cell responses and tumor cell recognition. SSS59 is a humanized antibody-based immunotherapy developed by Shenyang Sunshine Pharmaceuticals. The drug aims to redirect T cell cytotoxicity against tumor cells expressing MUC17 and is currently being evaluated in phase 1 clinical trials for safety, pharmacokinetics, and anti-tumor efficacy in patients with advanced malignancies[1][3][7][9][10].
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)MUC17 (Mucin 17, cell surface associated)
Beyond the preview
Go deeper on SSS59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSS59.